Alimera Sciences Reports Second Quarter 2023 Results
Alimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5...
Day: August 10, 2023
Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical...
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor...
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second...
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human...
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
- Continued Progress in Expanding and Advancing Clinical Pipeline -- Conference Call Today at 8:30 a.m. ET - ATLANTA, Aug....
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and...
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at...
Applied Therapeutics Reports Second Quarter 2023 Financial Results
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the...
Shockwave Medical Announces Proposed Private Offering of $500.0 Million of Convertible Senior Notes
SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave Medical”) announced today that it...
Tango Therapeutics Announces $80 million Private Placement Financing
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...